Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells – GlobeNewswire (press release)
|
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR–T cells
GlobeNewswire (press release) MONT-SAINT-GUIBERT, Belgium, May 30, 2017 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, today announced the issuance of United … |
